Publications

HDV: Severity of Disease

  1. Fattovich, G. et al; “Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B,” Gut 2000;46:420–426. (click to view PDF)
  2. Serrano, B, et al; “Comparing the Long-term Outcome of Hepatitis Delta and HBV Monoinfection: Is HDV-Infection Really Worse?” EASL 2011. (click to view PDF)

Prenylation

  1. Glenn, J. et al; “Identification of a Prenylation Site in Delta Virus Large Antigen,” Science, 1992; 1331-1333. (click to view PDF)
  2. Bordier, B. et al; “Prenylation Inhibitor Prevents Production of Infectious Hepatitis Delta Virus Particles,” J Virol, 2002; 10465-10472. (click to view PDF)

Long-term Clinical Benefit of Suppressing HDV-RNA

  1. Wranke, A. et al; “Antiviral Treatment and Liver-Related Complications in Hepatitis Delta,” Hepatology, 2016; 1-12. (click to view PDF)
  2. Farci, P. et al; “Long-Term Benefit of Interferon ! Therapy of Chronic Hepatitis D: Regression of Advanced Hepatic Fibrosis,” Gastroenterology, 2004; 126:1740–1749. (click to view PDF)
  3. Romeo, R. et al; “High Serum Levels of HDV RNA Are Predictors of Cirrhosis and Liver Cancer in Patients with Chronic Hepatitis Delta,” Plos One, 2015. (click to view PDF)
  4. Heidrich, B. et al; “Late HDV RNA Relapse After Peginterferon Alpha-Based Therapy of Chronic Hepatitis Delta,” Hepatology, 2014; 87-97. (click to view PDF)

Lonafarnib

  1. Koh, C. et al. “Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial,” Lancet Infect Dis, 2015; 15: 1167-74. (click to view PDF)

Pegylated Interferon Lambda

  1. Donnelly, R. et al; “Interferon-Lambda: A New Addition to an Old Family,” J Interferon Cytokine Res, 2016; 555-564. (click to view PDF)
  2. Giersch, K. et al; “Pegylated Interferon Lambda efficiently suppresses HDV productivity and shows comparable ability to induce ISGs as peg-IFNα in HBV/HDV co-infected humanized mice,” Monothematic Conf EASL 2013. (click to view PDF)

Presentations

Event Presentation Details Type PDF
AASLD, Nov 2014
Boston, MA
Koh, C. et al – “Prenylation Inhibition with Lonafarnib Decreases Hepatitis D Levels in Humans” Poster PDF Icon
AASLD, Nov 2014
Boston, MA
Koh, C. et al – “Prenylation Inhibition with Lonafarnib Decreases Hepatitis D Levels in Humans” Presentation PDF Icon
AASLD, Nov 2014
Boston, MA
Canini, L. et al – “Understanding hepatitis delta virus dynamic and antiviral efficacy of the prenylation inhibitor lonafarnib” Poster PDF Icon
EASL, Apr 2015
Vienna, Austria
Yurdaydin, C et al – “Optimizing the prenylation inhibitor lonafarnib using ritonavir boosting in patients with chronic delta hepatitis” Presentation PDF Icon
EASL, Apr 2016
Barcelona, Spain
Yurdaydin, C et al – “Hepatitis delta virus (HDV) kinetics under the prenylation inhibitor lonafarnib suggest HDV-mediated suppression of HBV replication.” Poster PDF Icon
EASL, Apr 2016
Barcelona, Spain
Canini, L. et al – “Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection.” Poster PDF Icon
HDV KOL/Analyst Event
May 2016, New York, NY
Advances in HDV Treatment Presentation PDF Icon
HDV KOL/Analyst Event
May 2016, New York, NY
Advances in HDV Treatment Webcast Webcast PDF Icon
PEG IFN Lambda, APR 2016 Public Disclosure Presentation PDF Icon
AASLD NOV 2016
Boston, MA
Yurdaydin, C. et al; “Exploring Optimal Dosing of Lonafarnib with Ritonavir for the Treatment of Chronic Delta Hepatitis.” Abstract #1845 Poster PDF Icon
AASLD NOV 2016
Boston, MA
Yurdaydin, C. et al; “The Prenylation Inhibitor Lonafarnib Can Induce Post-Treatment ALT Flares with Viral Clearance in Patients with Chronic Delta Hepatitis.” Abstract #1875 Poster PDF Icon